Technology
Medopad has acquired Sherbit – Business Insider
-
British health tech startup Medopad has acquired
Silicon Valley data firm Sherbit for an undisclosed sum, as
part of its US expansion. -
Medopad was founded in 2011, and helps hospitals and
patients track long-term conditions. -
Sherbit’s CEO and team will now focus on bringing
Medopad’s technology into US teaching hospitals. -
Medopad is planning to close a $120 million funding
round this year.
British health tech startup Medopad has bought Silicon Valley
health data service Sherbit for an undisclosed sum as part of its
expansion to the US.
Sherbit’s CEO, team, and advisory board will join Medopad and
focus on bringing its technology into teaching hospitals around
the US.
Medopad CEO Dan Vahdat said in a statement: “Sherbit has a strong
track record of success working with some of the most prestigious
healthcare organisations in the US, including the Mayo Clinic,
Tufts Medical Center and Jefferson Health.
“Through this acquisition, Medopad will provide its technology to
support solutions across different disease areas from rare
diseases to chronic conditions.”
Medopad is a digital health startup that tracks patients with
long-term illnesses and already has deals with British hospitals
including the Royal Free, Guy’s and St. Thomas’, and St.
Bartholomew’s. It also has $140 million in deals from Chinese
internet giant Tencent, and is planning to close a major Series A
round of $120 million (£86.4 million) in funding this year.
Sherbit is headquartered in San Francisco, and started life as a
data visualisation company which showed users a wide range of
metrics about their online activity, such as whether their
Twitter or Instagram posts were getting more likes.
After 2016, the company seems to have narrowed its focus to
quantified health. According to its site, Sherbit combines data
from a patient’s devices and wearables into a single dashboard.
That dashboard lets patients monitor areas like their sleep
levels and general fitness, and offers insights into how they can
become more healthy.
Medopad has expanded at a rapid clip this year, establishing not
only its partnerships and operations in China, but also opening
two New York offices. Dan Vahdat told Business Insider that
Medopad would boost its US team to around 30 people in the next
18 months.
The company said it had intentionally not raised money from
venture capitalists, instead winning backing from NWS
Holdings, a construction group and part of property giant New
World Development.
Vahdat said Medopad will announce the first fruits of its
partnership in Tencent in October. The company has signed a deal
with Chinese medical examination firm Ciming, and has another
major Chinese deal in the works, Vahdat added.
-
Business6 days ago
Xaira, an AI drug discovery startup, launches with a massive $1B, says it’s ‘ready’ to start developing drugs
-
Business7 days ago
UK probes Amazon and Microsoft over AI partnerships with Mistral, Anthropic, and Inflection
-
Entertainment5 days ago
Summer Movie Preview: From ‘Alien’ and ‘Furiosa’ to ‘Deadpool and Wolverine’
-
Business6 days ago
Petlibro’s new smart refrigerated wet food feeder is what your cat deserves
-
Entertainment4 days ago
What’s on the far side of the moon? Not darkness.
-
Business4 days ago
How Rubrik’s IPO paid off big for Greylock VC Asheem Chandna
-
Business5 days ago
Thoma Bravo to take UK cybersecurity company Darktrace private in $5B deal
-
Business4 days ago
TikTok faces a ban in the US, Tesla profits drop and healthcare data leaks